EC
TRAX

EcoR1 Capital’s First Tracks Biotherapeutics TRAX Stock Holding History

EcoR1 Capital’s Portfolio TRAX Stock Details TRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$63.9M Buy
+3,174,519
New +$59.3M 3.11% 8

Other funds holding TRAX

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JT
Jupiter Topco New York $245B AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

EcoR1 Capital's TRAX Position: Q2 2026 in Review

EcoR1 Capital opened a new position in First Tracks Biotherapeutics (TRAX) in Q2 2026: 3,174,519 shares worth $63.9M. The stake represents 3.11% of the portfolio and ranks #8 among its holdings.

136 funds tracked by Wall St. Rank hold TRAX as of Q2 2026.

  • EcoR1 Capital held 3,174,519 shares of First Tracks Biotherapeutics worth $63.9M as of Q2 2026.
  • First Tracks Biotherapeutics was a new EcoR1 Capital position in Q2 2026.
  • First Tracks Biotherapeutics made up 3.11% of EcoR1 Capital's portfolio in Q2 2026, its #8 holding.
  • 136 funds tracked by Wall St. Rank held First Tracks Biotherapeutics as of Q2 2026.

Based on EcoR1 Capital's 13F filing for Q2 2026, filed 14 Aug 2026.